Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.96 |
| ▸ | USP2 | O75604 | 4/20 | 0.96 |
| ▸ | RECQL | P46063 | 4/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.96 |
| ▸ | EGFR | P00533 | 1/20 | 0.96 |
| ▸ | LCK | P06239 | 1/20 | 0.96 |
| ▸ | FYN | P06241 | 1/20 | 0.96 |
| ▸ | KDM6B | O15054 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL31384812 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL1069135 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL29242657 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL30690154 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL1278779 | 1.00 | SLC7A5 (0.96) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL31471689 | 0.98 | SLC7A5 (0.93) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL28333192 | 0.98 | SLC7A5 (0.93) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL22655 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL20582239 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 | |
| Levodopa SCHEMBL704089 | 0.98 | SLC7A5 (1.00) | SLC7A5KDM4EALOX15HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12520840-B2 | Method for reducing parasite burden in a mosquito | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2026-01-13 | — | — | US | claimed |
| CN-120192260-A | Preparation method of 5, 6-dihydroxyindole | 宁夏大学 | 2025-06-24 | — | — | CN | claimed |
| CN-119746139-A | Water-sensitive in-situ ultrafast self-gel hemostatic powder and preparation method and application thereof | 四川大学 | 2025-04-04 | — | — | CN | claimed |
| CN-119192591-A | Dextran main chain zwitterionic polyamino acid side chain brush polymer and preparation and application thereof | 苏州大学 | 2024-12-27 | — | — | CN | claimed |
| US-20240025904-A1 | PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE | VANDERBILT UNIVERSITY | 2024-01-25 | — | — | US | claimed |
| CN-116847846-A | PDE9 inhibitors for the treatment of heart failure | 卡都瑞恩医药公司 | 2023-10-03 | — | — | CN | claimed |
| EP-4236951-A1 | PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE | Cardurion Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| WO-2022093852-A1 | PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE | Imara Inc. (US) | 2022-05-05 | — | — | WO | claimed |
| EP-4120958-B1 | IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-3424547-B1 | PACKAGING SYSTEM FOR OXYGEN-SENSITIVE DRUGS | FRESENIUS KABI AUSTRIA GMBH (AT) | 2026-02-11 | — | — | EP | disclosed |
| US-12520840-B2 | Method for reducing parasite burden in a mosquito | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2026-01-13 | — | — | US | disclosed |
| US-12390429-B2 | Chemically and physically stable topical ophthalmic nepafenac-based formulations | MEDIVIS S.R.L. (IT) | 2025-08-19 | — | — | US | disclosed |
| US-20250144061-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-08 | — | — | US | disclosed |
| EP-4549633-A1 | CYANIDE-FREE SILVER BATH COMPOSITION AND USES THEREOF | AXON CABLE (FR) | 2025-05-07 | — | — | EP | disclosed |
| US-20220096404-A1 | CHEMICALLY AND PHYSICALLY STABLE TOPICAL OPHTHALMIC NEPAFENAC-BASED FORMULATIONS | MEDIVIS S.R.L. (IT) | 2022-03-31 | — | — | US | disclosed |
| US-20220079906-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-03-17 | — | — | US | disclosed |
| US-20220079907-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-03-17 | — | — | US | disclosed |
| CN-114129772-A | Preparation method of composite scaffold for bone tissue engineering | 上海浩渤医疗科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-114113614-A | Tannin immune network and clenbuterol hydrochloride test strip detection method | 西北农林科技大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-114099778-A | Composite scaffold for bone tissue engineering | 上海市浦东新区人民医院 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144061-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | LIPA, LIPC, PNLIP | DRD3 2413/4885SLC7A5 3129/4885KDM4E 2721/4885 |
| US-20220079907-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | LIPA, LIPC, PNLIP | DRD3 2413/4885SLC7A5 3129/4885KDM4E 2721/4885 |
| US-20220079906-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | LIPA, LIPC, PNLIP | DRD3 2413/4885SLC7A5 3129/4885KDM4E 2721/4885 |
| US-20240025904-A1 | PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE | PDE9A, PDE2A, PDE5A | DRD3 4852/4885SLC7A5 4678/4885KDM4E 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.